The Filing Desk

Teva Pharmaceuticals vs Universe Pharmaceuticals

Teva Pharmaceuticals TEVA · Universe Pharmaceuticals UPC · Pharmaceuticals

Universe Pharmaceuticals reported revenue of $17.9 billion in fiscal 2025, about the same as Teva Pharmaceuticals' $17.3 billion in fiscal 2025. Teva Pharmaceuticals' revenue grew 4.3% in its latest year, and Universe Pharmaceuticals' fell 22.4%. Teva Pharmaceuticals had an operating margin of 12.5%, against -16.3% at Universe Pharmaceuticals. Free cash flow was $1.1 billion at Teva Pharmaceuticals and −$5.3 billion at Universe Pharmaceuticals. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

Teva PharmaceuticalsUniverse Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Sep 30, 2025
Revenue$17.3B$17.9B
Revenue growth4.3%−22.4%
Revenue growth a year, last 5 years0.7%257.2%
Gross margin51.8%35.3%
Operating margin12.5%−16.3%
Net margin8.2%−20.6%
Free cash flow$1.1B−$5.3B
Free cash flow margin6.7%−29.8%
Return on capital10.5%—
Net debt to EBITDA4.2x—
Dividends and buybacks$0M$0M
Change in diluted share count2.8%3,174.9%
Last close$38.54$1.36
P/E at the last close89.6×—
Insider trades, last 12 monthssold $125.1 million—
Piotroski F-score8 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Teva PharmaceuticalsUniverse Pharmaceuticals
Operating margin
Percent of revenue
Teva PharmaceuticalsUniverse Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Teva PharmaceuticalsUniverse Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Teva Pharmaceuticals and Universe Pharmaceuticals pages.